WeVote
Log In

Bill

Bill

SB 1724

SB 1724 - This act makes xylazine a Schedule III controlled substance, except for certain uses described in the act, including manufacturing a drug for an animal or administering the drug to an animal. This act is substantially similar to HB 1881 (2026). SARAH HASKINS

2026 Regular Session Introduced by Justin Brown

SB 1724 classifies xylazine as Schedule III, establishing criminal penalties for possession and distribution of the veterinary sedative increasingly found in illicit drug supplies.

Second Read and Referred S Judiciary and Civil and Criminal Jurisprudence Committee
0
WeVote Research Nonpartisan
Bill Summary · SB 1724

Legislative bill overview

SB 1724 would classify xylazine as a Schedule III controlled substance under Missouri law. Xylazine is a veterinary sedative increasingly found in illicit drug supplies, particularly mixed with opioids and other substances. This reclassification would establish criminal penalties for unauthorized possession and distribution of the drug.

Why is this important

Xylazine has emerged as a significant public health concern, appearing in counterfeit pills and street drugs without users' knowledge, complicating overdose treatment and creating additional health risks. The reclassification would give law enforcement tools to address its distribution and potentially signal the state's commitment to addressing emerging drug threats. However, it may also affect legitimate veterinary and medical uses if not carefully exempted.

Potential points of contention

  • Medical/veterinary access: Schedule III classification could complicate legitimate clinical and veterinary uses if adequate exemptions aren't included for licensed practitioners
  • Criminal justice impact: Adds another drug to the criminal justice system, potentially increasing incarceration rates without addressing underlying addiction and distribution networks
  • Effectiveness questions: Scheduling alone doesn't eliminate illicit supply; critics argue resources should focus on treatment, harm reduction, and addressing root causes of drug mixing

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.